BMC Pulmonary Medicine最新文献

{"title":"Comparing spirometry, impulse oscillometry with computed tomography for assessing small airway dysfunction in subjects with and without chronic obstructive pulmonary disease.","authors":"Suyin Huang, Fan Wu, Zhishan Deng, Jieqi Peng, Cuiqiong Dai, Lifei Lu, Kunning Zhou, Xiaohui Wu, Qi Wan, Gaoying Tang, Shengtang Chen, Changli Yang, Yongqing Huang, Shuqing Yu, Pixin Ran, Yumin Zhou","doi":"10.1186/s12890-025-03507-1","DOIUrl":"10.1186/s12890-025-03507-1","url":null,"abstract":"<p><strong>Background: </strong>Studies on consistency among spirometry, impulse oscillometry (IOS), and histology for detecting small airway dysfunction (SAD) remain scarce. Considering invasiveness of lung histopathology, we aimed to compare spirometry and IOS with chest computed tomography (CT) for SAD detection, and evaluate clinical characteristics of subjects with SAD assessed by these three techniques.</p><p><strong>Methods: </strong>We collected baseline data from the Early COPD (ECOPD) study. CT-defined SAD was defined as parametric response mapping quantifying SAD (PRM^fSAD) ≥ 15%. Spirometry-defined SAD was defined as at least two of maximal mid-expiratory flow (MMEF), forced expiratory flow 50% (FEF50), and forced expiratory flow 75% (FEF75) less than 65% of predicted. IOS-defined SAD was defined as peripheral airway resistance R5 - R20 > 0.07 kPa/L/s. The consistency of spirometry, IOS and CT for diagnosing SAD was assessed using Kappa coefficient. Correlations among the three techniques-measured small airway function parameters were assessed by Spearman correlation analysis.</p><p><strong>Results: </strong>2055 subjects were included in the final analysis. There was low agreement in SAD assessment between spirometry and CT (Kappa = 0.126, 95% confidence interval [CI]: 0.106 to 0.146, p < 0.001), between IOS and CT (Kappa = 0.266, 95% CI: 0.219 to 0.313, p < 0.001), as well as among spirometry, IOS, and CT (Kappa = 0.056, 95% CI: 0.029 to 0.082, p < 0.001). The correlation was moderate (|r|: 0.5 to 0.7, p < 0.05) between spirometry and CT-measured small airway function parameters, and weak (|r|< 0.4, p < 0.05) between IOS and CT-measured small airway function parameters. Only spirometry-defined SAD group had more lower lung function (FEV₁/FVC: adjusted difference=-10.7%, 95% CI: -13.5% to -7.8%, p < 0.001) and increased airway wall thickness (Pi 10: adjusted difference = 0.3 mm, 95% CI: 0 to 0.6 mm, p = 0.046) than only CT-defined SAD group. Only IOS-defined SAD group had better lung function (FEV₁/FVC: adjusted difference = 3.9%, 95% CI: 1.9 to 5.8%, p < 0.001), less emphysema (inspiratory LAA_- 950: adjusted difference=-2.1%, 95% CI:-3.1% to -1.1%, P < 0.001; PRM^Emph: adjusted difference=-2.3%, 95% CI: -3.2% to -1.4%, p < 0.001), and thicker airway wall (Pi 10: adjusted difference = 0.2 mm, 95% CI: 0.1 mm to 0.4 mm, p = 0.005) than only CT-defined SAD group.</p><p><strong>Conclusions: </strong>There was low consistency in the assessment of SAD between spirometry and CT, between IOS and CT, as well as among spirometry, IOS, and CT.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"45"},"PeriodicalIF":2.6,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary langerhans cell histiocytosis secondary to Marijuana use: a case report and systematic review of the literature.","authors":"Ibrahim Zahid, Aruba Sohail, Roohan Tahir, Matthew Belardo, Brandon Hooks","doi":"10.1186/s12890-025-03513-3","DOIUrl":"10.1186/s12890-025-03513-3","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary Langerhans Cell Histiocytosis (PLCH) is a rare interstitial lung disease primarily affecting young to middle-aged smokers. While traditionally linked to tobacco use, there is growing evidence that cannabis use may contribute to PLCH.</p><p><strong>Methods: </strong>We present a case of a 52-year-old male with PLCH associated with heavy cannabis use. Diagnostic evaluations included CT scan of the chest and histopathological examination of a lung biopsy. In addition, a comprehensive review of the literature was conducted to identify and analyze similar cases of PLCH linked to cannabis use. Databases searched included PubMed and Google Scholar, following PRISMA guidelines.</p><p><strong>Results: </strong>The patient presented with dyspnea, cough and unintentional weight loss. The patient had a 20-year history of smoking approximately ten cannabis blunts per day. Despite normal initial chest X-ray findings, a CT scan of his chest revealed upper lobe predominant cystic changes and emphysema. Histopathology from a transbronchial biopsy confirmed the presence of Langerhans cells, consistent with PLCH. Literature review identified five additional case reports of PLCH associated with cannabis use, involving patients aged 16 to 59 years, with a mean age of 35.8 years. Common clinical presentations included cough, dyspnea, and chest pain, with radiographic findings of nodules and cysts. Treatment was primarily targeted towards smoking cessation, which led to clinical improvement in all cases.</p><p><strong>Conclusions: </strong>This case underscores the potential association between heavy cannabis use and the development of PLCH. With the increasing prevalence of cannabis consumption, it is essential to recognize cannabis as a possible risk factor for PLCH. Further research is needed to understand the pathophysiological mechanisms underlying cannabis-related PLCH. As cannabis use becomes more prevalent with changing legislation, understanding its impact on lung health and potential role in diseases like PLCH is increasingly important.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"44"},"PeriodicalIF":2.6,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for disease progression and clinical outcomes in patients with COVID-19 in Taiwan: a nationwide population-based cohort study.","authors":"Raymond N Kuo, Wanchi Chen, Wen-Yi Shau","doi":"10.1186/s12890-024-03468-x","DOIUrl":"10.1186/s12890-024-03468-x","url":null,"abstract":"<p><strong>Background: </strong>Since 2021, COVID-19 has had a substantial impact on global health and continues to contribute to serious health outcomes. In Taiwan, most research has focused on hospitalized patients or mortality cases, leaving important gaps in understanding the broader effects of the disease and identifying individuals at high risk. This study aims to investigate the risk factors for disease progression through a nationwide population-based cohort study on COVID-19 in Taiwan.</p><p><strong>Methods: </strong>This study included 15,056 patients diagnosed with COVID-19 between January 1, 2021, and December 31, 2021, using the Taiwan National Health Insurance Research Database. Baseline and clinical characteristics were collected to verify the association with progression to severity outcomes, including hospital admission, intensive care unit (ICU) admission, invasive ventilatory support, fatal outcome, and the composite outcome of these four events. Patients were observed for 30 days for disease progression. Multivariable logistic regression models were used to calculate odd ratios and 95% confidence intervals (CIs) for each outcome, adjusting for age, sex, region, risk factors, and vaccination status.</p><p><strong>Results: </strong>Overall, 8,169 patients diagnosed during outpatient visits and 6,887 patients diagnosed during hospitalization were analyzed. Adjusting for age, sex, region, risk factors, and vaccination status, elderly patients had higher risks of hospital admission, ICU admission, invasive ventilatory support, fatal outcome, and composite outcome. Specifically, the risk of the fatal outcome was significantly higher for patients aged 75-84 (odds ratio: 6.11, 95% CI: 4.75-7.87) and those aged 85 years and older (12.70, 9.48-17.02). Patients with cardiovascular disease exhibited higher risks of hospital admission (1.60, 1.31-1.96), ICU admission (1.52, 1.31-1.78), invasive ventilatory support (1.57, 1.26-1.96), and fatal outcomes (1.26, 1.03-1.54) and the composite outcome (1.66, 1.20-1.54). Diabetes mellitus was identified as a significant risk factor for all clinical outcomes (hospital admission: 1.89, 1.53-2.35; ICU admission: 1.53, 1.30-1.79; invasive ventilatory support: 1.27, 1.01-1.60; the composite outcome: 1.45, 1.28-1.66), except for the fatal outcome.</p><p><strong>Conclusions: </strong>This study indicated the impact of sex, age, and risk factors on the clinical outcomes of COVID-19 patients in Taiwan. Elderly patients and those with cardiovascular disease or diabetes mellitus had higher risks for severe outcomes, including hospitalization, ICU admission, invasive ventilatory support, and mortality. These findings can provide evidence for a better understanding of risk factors for disease progression and inform targeted intervention.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"43"},"PeriodicalIF":2.6,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11765924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Massive endobronchial hemorrhage leading to Cardiac arrest during EBUS-TBNA: a case of successful resuscitation.","authors":"Ping-Yang Hong, Mao-Hong Huang, Ling Cai, Yi-Yuan Chen, Yu-Xin Guo, Xiao-Bin Zhang","doi":"10.1186/s12890-025-03503-5","DOIUrl":"10.1186/s12890-025-03503-5","url":null,"abstract":"<p><strong>Introduction: </strong>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is commonly used for diagnosing mediastinal lymphadenopathy. Despite a low complication rate, severe hemorrhage can occur which is reported in this literature, particularly in hypervascular conditions like Castleman disease.</p><p><strong>Methods: </strong>A 54-year-old male with idiopathic multicentric Castleman disease underwent EBUS-TBNA for mediastinal lymph node sampling. During the procedure, vascular invasion led to significant bleeding, requiring immediate interventions including suctioning and therapeutic bronchoscopy.</p><p><strong>Results: </strong>The patient experienced massive hemorrhage, resulting in airway obstruction, oxygen desaturation, and cardiac arrest. Aggressive resuscitation successfully restored cardiac rhythm after 15 min. The patient was then stabilized and transferred to the intensive care unit for monitoring.</p><p><strong>Conclusions: </strong>This case underscores the risk of severe hemorrhage in hypervascular conditions during EBUS-TBNA. Pre-procedural imaging, careful planning, and immediate availability of hemostatic measures are crucial to reducing complications and improving outcomes in high-risk patients.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"42"},"PeriodicalIF":2.6,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11765929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study.","authors":"Hongxia Xin, Ping He, Bin Xi, Zhaojun Wang, Han Wang, Faxuan Wang, Zhanbing Ma, Jing Xue, Yuanyuan Jia, Hourong Cai, Bi Chen, Juan Chen","doi":"10.1186/s12890-025-03512-4","DOIUrl":"10.1186/s12890-025-03512-4","url":null,"abstract":"<p><strong>Background: </strong>In this study, we aimed to explore the association between baseline and early changes in the neutrophil-to-lymphocyte ratio (NLR) and the 30-day mortality rate in patients having anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD).</p><p><strong>Methods: </strong>Overall, 263 patients with anti-MDA5 DM-ILD from four centers in China were analyzed. Multivariate logistic regression analysis was used to evaluate the impact of baseline NLR on the 30-day mortality rate in patients with anti-MDA5-positive DM-ILD. Furthermore, a generalized additive mixed model (GAMM) was applied to compare the NLR variations over time between 30-day survival group and non-survival group.</p><p><strong>Results: </strong>Two hundred sixty-three patients with anti-MDA5-positive DM-ILD were divided into different groups based on their NLR and whether they survived or not within 30 days. The multivariate logistic regression analysis, accounting for confounding factors, identified an elevated baseline NLR as a prognostic indicator for 30-day mortality in patients with anti-MDA5-positive DM-ILD (hazard ratio 2.68, 95% confidence interval [CI] 1.18,6.00, P = 0.019). Furthermore, the GAMM results indicated that the NLR gradually increased more in the non-survival group compared with the survival group within 14 days of admission, with a daily average increase of 1.03 (β = 1.03; 95% CI, 0.75-1.31; P < 0.001).</p><p><strong>Conclusions: </strong>We found that an elevated baseline NLR and its progressive increase are associated with 30-day mortality in patients with anti-MDA5-positive DM-ILD.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"40"},"PeriodicalIF":2.6,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.","authors":"Negar Alizadeh, Hoda Zahedi, Maryam Koopaie, Mahnaz Fatahzadeh, Reza Mousavi, Sajad Kolahdooz","doi":"10.1186/s12890-025-03502-6","DOIUrl":"10.1186/s12890-025-03502-6","url":null,"abstract":"<p><strong>Objective: </strong>Lung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily. The process is also reproducible and cost-effective. The aim of this study was to evaluate the salivary expression of microRNAs let-7a-2, miR-221, and miR-20a in saliva and evaluate their efficacy, using multiple logistic regression (MLR) model, in diagnosis of lung cancer.</p><p><strong>Materials: </strong>Samples of saliva were obtained from 40 lung cancer patients (20 lung adenocarcinoma and 20 lung squamous cell carcinoma) and 20 healthy controls. The levels of let-7a-2, miR-221, and miR-20a expression in saliva were assessed by RT-qPCR. Receiver operating characteristic (ROC) curve was utilized to assess the potential significance of miRNAs in saliva for lung cancer diagnosis with the use of multiple logistic regression (MLR), principal component analysis, and machine learning methods.</p><p><strong>Results: </strong>Diagnostic odds ratio (DOR) of miR-20a in lung adenocarcinoma diagnosis versus healthy control was higher than miR-221, and DOR of miR-221 was higher than let-7a-2. miR-20a demonstrated a higher DOR for small cell lung carcinoma versus healthy control compared to let-7a-2, which in turn exhibited a higher DOR than miR-221. MLR of miR-221, let-7a-2, miR-20a, and smoking habit using main effects led to accuracy of 0.725 (sensitivity: 0.80, specificity: 0.65) and AUC = 0.795 for differentiation of small-cell lung carcinoma from lung adenocarcinoma. Our results showed that MLR based on salivary miRNAs could diagnose LUAD and SCLC from healthy control using main effects and two-way interactions with the accuracy of 0.90 (sensitivity = 0.95 and specificity = 0.85).</p><p><strong>Conclusion: </strong>A salivary miRNA-based MLR model is a promising diagnostic tool for lung cancer, offering a non-invasive screening option for high-risk asymptomatic individuals.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"41"},"PeriodicalIF":2.6,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11765895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eight patients with inflammatory myofibroblastic tumor treated with rigid bronchoscopy.","authors":"Byeong-Ho Jeong, Rong Lih Ho, Ho Yun Lee, Joungho Han, Hojoong Kim","doi":"10.1186/s12890-025-03476-5","DOIUrl":"10.1186/s12890-025-03476-5","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary inflammatory myofibroblastic tumor (IMT) accounts for 0.04-0.7% of all lung tumors, and endobronchial IMT accounts for only 10% of all pulmonary IMTs. Little is known about the therapeutic outcomes of rigid bronchoscopy for endobronchial IMT. Here, we report a case series of eight patients with endobronchial IMT underwent rigid bronchoscopy.</p><p><strong>Methods: </strong>We retrospectively analyzed eight patients with endobronchial IMT between January 2004 and December 2023.</p><p><strong>Results: </strong>The median age of our patients was 36 years, and 62.5% were male. Dyspnea was the predominant symptom in cases where the tumor was centrally located (n = 6), whereas hemoptysis was the predominant symptom in peripherally located tumors (n = 2). Most cases had high contrast enhancement and a tumor stalk without bronchial wall invasion on computed tomography (CT) and bronchoscopy. Complete endoscopic resection and laser cauterization via rigid bronchoscopy were possible in five patients. There were only two cases in which tumors remained after the procedure, requiring additional treatment (chemotherapy and surgical resection, respectively). In one patient, surgical resection was performed three weeks after the procedure, and the surgical specimen was free of residual tumor. There was no mortality during the median follow-up duration of 18.8 months.</p><p><strong>Conclusions: </strong>Endoscopic resection and laser cauterization using rigid bronchoscopy may serve as a safe and effective alternative treatment modality to surgery for patients with endobronchial IMT.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"37"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in idiopathic pulmonary fibrosis in Latin American countries.","authors":"H Aguilar-Duran, M Fernández, M González-García, E Rincón-Alvarez, M Alberti, F Caro, E Tavera, E Vásquez, N Cortez, M Salinas, M Florenzano, C Florestano, Ivette Buendia-Roldan","doi":"10.1186/s12890-025-03506-2","DOIUrl":"10.1186/s12890-025-03506-2","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is the most common Interstitial Lung Disease (ILD). It is characterized by dyspnoea and a progressive decline in lung function, which negatively affects life. This study aimed to evaluate Health-Related Quality of Life (HRQoL) in IPF patients in Latin American countries.</p><p><strong>Methods: </strong>Six countries (Argentina, Bolivia, Colombia, Chile, Mexico, and the Dominican Republic) enrolled patients with IPF. They answered the Saint George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis (SGRQ-I) and the Hospital Anxiety and Depression Scale (HADS). Demographic characteristics, the Torvan index, and a lung function test were also assessed. IPF was diagnosed according to the ATS/ERS/JRS/ALAT 2018 criteria.</p><p><strong>Results: </strong>We enlisted 75 patients diagnosed with IPF; 81% were male, with an average age of 74 ± 7. The total SGRQ-I score was 49 ± 23, with a higher score in the activity domain of 70 ± 23. Torvan index average was 17 ± 6. We found that 28% presented anxiety and 35% depression. Besides, we observed that patients requiring oxygen had a worse quality of life (total SGRQ-I 62 ± 22 vs. 45 ± 22, p = 0.003) without finding differences in antifibrotic therapy. We did not find differences in HRQoL when dividing groups according to their altitude above sea level, except for a higher frequency of anxiety in patients living at sea level.</p><p><strong>Conclusions: </strong>We found similar data compared to those reported in real-life European populations. We also found that anxiety and depression are prevalent. However, they are often underdiagnosed and, therefore, left untreated.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"36"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic rigid bronchoscopy for endobronchial glomus tumors: a case series.","authors":"Rong Lih Ho, Byeong-Ho Jeong, Joungho Han, Hojoong Kim","doi":"10.1186/s12890-024-03466-z","DOIUrl":"10.1186/s12890-024-03466-z","url":null,"abstract":"<p><strong>Background: </strong>Glomus tumors (GTs) are rare, comprising only 2% of all soft tissue tumors. Pulmonary GTs are exceptionally rare, with fewer than 80 cases reported to date. Little is known about the therapeutic outcomes of rigid bronchoscopy for endobronchial GT.</p><p><strong>Methods: </strong>This is a case series of four patients with endobronchial GT who underwent therapeutic rigid bronchoscopy between February 2021 and June 2024.</p><p><strong>Results: </strong>The ages of the patients in our series ranged from 32 to 75 years, and all patients were male. Cough and blood-tinged sputum were present in all patients with endobronchial GT. The tumor sizes ranged from 1 to 3 cm. Complete endoscopic resection and laser cauterization via rigid bronchoscopy were achieved in two patients. One patient had incomplete resection of a 3-cm tumor in the segmental bronchus that showed radiological evidence of bronchial wall invasion. This patient subsequently underwent lobectomy seven months after bronchoscopic resection. The fourth patient was lost to follow-up. There was no mortality throughout the follow-up periods that ranged from 2.8 to 42.5 months. Factors favoring successful rigid bronchoscopy resection for endobronchial GT include a benign tumor in the central airways without bronchial wall invasion.</p><p><strong>Conclusion: </strong>Endoscopic resection and laser cauterization using rigid bronchoscopy may be a viable option for patients with endobronchial GT when surgery is not practical.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"39"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of exercise intensity on nutritional status, body composition, and energy balance in patients with COPD: a randomized controlled trial.","authors":"Tomoyuki Ikeuchi, Kazuya Shingai, Katsuyuki Ichiki, Takeo Jimi, Tetsuya Kawano, Kaori Kato, Toru Tsuda","doi":"10.1186/s12890-024-03448-1","DOIUrl":"10.1186/s12890-024-03448-1","url":null,"abstract":"<p><strong>Background: </strong>High-intensity exercise is recommended for the pulmonary rehabilitation of patients with chronic obstructive pulmonary disease (COPD); however, it can cause an energy imbalance due to increased energy expenditure. Here, we aimed to explore the effect of reducing exercise intensity on energy balance in patients with COPD experiencing high-intensity training-induced weight loss.</p><p><strong>Methods: </strong>All participants underwent high-intensity endurance and resistance training for a 2-week preliminary period. Those who lost more than 1% of their weight were then randomized to either continue high-intensity exercise (AA group) or switch to low-intensity exercise (AB group) for another 2 weeks (experimental period).</p><p><strong>Results: </strong>The analysis included 30 participants (AA, n = 15; AB, n = 15). The AA group showed significant increases in body composition, dietary intake, nutritional status, muscle strength, and exercise capacity at week 4 than at week 2, with no significant changes in the AB group. After the experimental period, a greater proportion of the AA group had energy intake exceeding expenditure than did the AB group (80% vs. 40%).</p><p><strong>Conclusions: </strong>In patients with COPD who lost body weight during pulmonary rehabilitation with high-intensity exercise, continuing this exercise had a more positive effect on body composition, nutritional status, physical function, and energy balance than did reducing exercise intensity. These results suggest the importance of continuing high-intensity exercise, while taking into consideration energy intake and nutritional therapy, even when body weight loss occurs during pulmonary rehabilitation in patients with COPD.</p><p><strong>Trial registration: </strong>This study was retrospectively registered on the UMIN-CTR as UMIN000050976 on May 5, 2023.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"34"},"PeriodicalIF":2.6,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}